Update on therapeutic options for Helicobacter pylori-related diseases

被引：45

作者：

Mégraud F. ^{[1
]}

机构：

[1] Laboratoire de Bactériologie, Hôpital Pellegrin

来源：

Current Infectious Disease Reports | 2005年 / 7卷 / 2期

关键词：

Metronidazole; Pylorus Infection; Clarithromycin; Triple Therapy; Pylorus Eradication;

D O I：

10.1007/s11908-005-0071-4

中图分类号：

学科分类号：

摘要：

Triple therapy including clarithromycin, amoxicillin, and a proton pump inhibitor (PPI) has been recommended as the treatment of choice for Helicobacter pylori eradication. This regimen is now challenged by an increasing level of clarithromycin resistance that jeopardizes the treatment success. When clarithromycin resistance has been detected, or when its rate is known to be high in the geographic area, this drug cannot be used. It can be replaced by metronidazole, the resistance of which has a limited clinical relevance. Another option is to prescribe tetracycline and metronidazole with a PPI or ranitide bismuth citrate. New antibiotics such as levofloxacin or rifabutin can also be used in combination with amoxicillin and a PPI. Probiotics can be added to all of these regimens to improve compliance by decreasing adverse events. But some authors advocate a quadruple therapy as a first-line treatment. Solutions to improve the limitations of this last regimen are now being proposed. Clarification of the controversial treatment indications such as gastroesophageal reflux disease or prevention of nonsteroidal anti-inflammatory drug gastroduodenal symtoms has been made. The question of prevention of gastric carcinoma by H.pylori eradication remains unanswered. Copyright © 2005 by Current Science Inc.

引用

页码：115 / 120

页数：5

共 52 条

[41]

Sakamoto I., Igarashi M., Kimura K., Et al., Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infections in humans, J. Antimicrob. Chemother., 47, pp. 709-710, (2001)

[42]

Nista E.C., Candelli M., Cremonini F., Et al., Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: Randomized, double-blind, placebo controlled trial, Aliment Pharmacol. Ther., 20, pp. 1181-1188, (2004)

[43]

Fishbach L.A., Zanten S.V., Dickason J., Meta-analysis: The efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies, Aliment Pharmacol. Ther., 20, pp. 1071-1082, (2004)

[44]

Graham D.Y., Belson G., Abudayyeh S., Et al., Twice daily (midday and evening) quadruple therapy for H. pylori infection in the United States, Dig. Liver Dis., 36, pp. 384-387, (2004)

[45]

O'Morain C., Borody T., Farley A., Et al., Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: An international multicentre study, Aliment Pharmacol. Ther., 17, pp. 415-420, (2003)

[46]

Laine L., Hunt R., El-Zimaity H., Et al., Bismuth-based quadruple therapy using a capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: A prospective, randomized, multicenter, North American trial, Am. J. Gastroenterol., 98, pp. 562-567, (2003)

[47]

Ford A.C., Delaney B.C., Forman D., Moayyedi P., Eradication therapy in Helicobacter pylori positive peptic ulcer disease: Systematic review and ecomomic analysis, Am. J. Gastroenterol., 99, pp. 1833-1855, (2004)

[48]

Malfertheiner P., Helicobacter pylori eradication does not exacerbate gastro-oesophageal reflux disease, Gut, 53, pp. 312-313, (2004)

[49]

Axon A.T., Personal view: To treat or not to treat? Helicobacter pylori and gastro-oesophageal reflux disease-an alternative hypothesis, Aliment Pharmacol. Ther., 19, pp. 253-261, (2004)

[50]

Hunt R.H., Bazzoli F., Review article: Should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing, Aliment Pharmacol. Ther., 19, SUPPL. 1, pp. 9-16, (2004)

← 1 2 3 4 5 6 →